NCT00382590View on ClinicalTrials.gov

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Acute Myelogenous LeukemiaMyelodysplastic SyndromeLeukemia
Interventions
DRUG

5-Azacytidine

75 mg/m\^2 daily for 7 days (days 1-7) via subcutaneous injection.

DRUG

Ara-C

20 mg twice daily via subcutaneous injection for 10 days.

DRUG

Valproic Acid (VPA)

50 mg/m\^2 orally daily days 1-7.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00382590 - Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | Biotech Hunter | Biotech Hunter